Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma

NCT03313206 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Immune Profiles Evolution Under Immunotherapy for Melanoma

NCT04576429 ·Status: RECRUITING ·Phase: NA

Intratumoral Injection Of Alpha-Gal Glycosphingolipids

NCT00668512 ·Status: COMPLETED ·Phase: PHASE1

Understanding and Anticipating Therapeutic Response And Immuno-meDIated Adverse Events in Anti-cancer Immune-checkpoint Inhibition: a Tissue Biopsy Based imaGing Study

NCT05921123 ·Status: RECRUITING

Immune Monitoring in Metastatic Melanoma

NCT04158544 ·Status: UNKNOWN

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

NCT00896480 ·Status: COMPLETED ·Phase: PHASE2

Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma

NCT05527795 ·Status: RECRUITING

Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma

NCT03225365 ·Status: COMPLETED ·Phase: NA

Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics

NCT03643289 ·Status: UNKNOWN

Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma

NCT02694965 ·Status: COMPLETED

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

NCT01253096 ·Status: COMPLETED ·Phase: PHASE2

One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy

NCT06809491 ·Status: ACTIVE_NOT_RECRUITING

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

NCT01213472 ·Status: COMPLETED ·Phase: PHASE1

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

NCT05984615 ·Status: COMPLETED

A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT01066390 ·Status: COMPLETED ·Phase: PHASE1

IMCgp100-401 Rollover Study

NCT02889861 ·Status: TERMINATED ·Phase: PHASE2

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

NCT00055562 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes

NCT02310451 ·Status: COMPLETED ·Phase: NA

Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients

NCT05029791 ·Status: RECRUITING ·Phase: NA

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

NCT03625141 ·Status: COMPLETED ·Phase: PHASE2

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872 ·Status: COMPLETED ·Phase: PHASE2

Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors

NCT05649683 ·Status: RECRUITING ·Phase: NA

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

NCT03696069 ·Status: COMPLETED

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

NCT02828202 ·Status: RECRUITING